Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Gene Therapy Membrane-virus-host-range-mutations-and-their-uses-as-vaccine-substrates

 Solid phase dispersion of quinolone or naphthyridonecarboxylic acids
What is claimed is: 1. A solid phase dispersion comprising a micronized quinolinecarboxylic acid or ...


 Peptide, process for its preparation and pharmaceutical composition containing same
We claim: 1. pGlu-Pro-Pro-Gly-Gly-Ser-Lys-Val-Ile-Leu-Phe. 2. A pharmaceutical composition for cell-...


 Stable pharmaceutical composition and method for its production
It is an object of the present invention to provide a stable pharmaceutical composition wherein the ...


 Pharmaceutical composition for treatment of adult respiratory distress syndrome containing human ANP
The present invention has been accomplished under these circumstances and has as an object ...


 Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
OF THE PREFERRED EMBODIMENT The following standard abbreviations for the amino acid residues are ...


 Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
The invention provides an isolated peptide that functionally mimics a binding site for a ...


 Adjuvant and vaccine compositions containing monophosphoryl lipid A
What is claimed: 1. A lyophilized composition comprising 0.2% up to 5% by weight 3-O-desacyl-4'-...


 Methods for preparation of vaccines against cancer
The present invention relates to methods for producing increased amounts of immunogenic material ...


 Human genes and gene expression products V
OF THE INVENTION The invention relates to polynucleotides comprising the disclosed nucleotide ...


 Haptotactic peprides
The invention claimed is: 1. An isolated haptotactic peptide of 20 amino acids consisting of the ...


 Membrane virus host range mutations and their uses as vaccine substrates

Details
Inventors: Hernandez, Racquel; Brown, Dennis T.;
Assignee: Research Development Foundation (Carson City, NV)
Primary Examiner: Parkin; Jeffrey S.
Assistant Examiner:
Attorney, Agent or Firm: Fulbright & Jaworski LLP

The present invention is directed to genetically engineered, membrane-enveloped viruses with deletion mutations in the protein transmembrane domains. Also provided are viral vaccines based on the engineered viruses, methods of producing and using such vaccines.

DETAILED DESCRIPTION What is claimed is: 1.
A genetically engineered Arbovirus comprising, a transmembrane glycoprotein with a deletion of one or more amino acids in a transmembrane domain wherein, said virus is capable of infecting and producing progeny virus in insect cells, wherein said engineered Arbovirus has an ability to infect mammalian cells but a reduced ability to replicate therein relative to wild type virus.
2.
The genetically engineered Arbovirus of claim 1, wherein the insect cells are mosquito cells.
3.
The genetically engineered Arbovirus of claim 2, wherein the mosquito cells are Aedes ablbopictus cells.
4.
The genetically engineered Arbovirus of claim 1, wherein said virus produces at least 1,000 fold more progeny virus when infecting insect cells than when infecting mammalian cells.
5.
The genetically engineered Arbovirus of claim 4, wherein said virus produces at least 10,000 fold more progeny virus when infecting insect cells than when infecting mammalian cells.
6.
The genetically engineered Arbovirus of claim 1, wherein the transmembrane glycoprotein has a deletion of nine or more amino acids in a transmembrane domain.
7.
The genetically engineered Arbovirus of claim 1, wherein the genetically engineered Arbovirus is a genetically engineered Togavirus, Flavivirus or Bunyavirus.
8.
The genetically engineered Arbovirus of claim 7, wherein the genetically engineered Togavirus is a genetically engineered Alphavirus.
9.
The genetically engineered Arbovirus of claim 8, wherein said transmembrane glycoprotein is glycoprotein E1, or glycoprotein E2.
10.
The genetically engineered Arbovirus of claim 9, wherein the genetically engineered Alphavirus is a genetically engineered Sindbis virus.
11.
The genetically engineered Arbovirus of claim 10, wherein said genetically engineered Sindbis virus is the TM16 virus.
12.
The genetically engineered Arbovirus of claim 10, wherein said genetically engineered Sindbis virus is the .
DELTA.
K391 virus.
13.
The genetically engineered Arbovirus of claim 10, wherein said genetically engineered Sindbis virus is the TM17 virus



Related patents
  Aminoethylation process for production of substituted ethylene diamines
What is claimed is: 1. A process for preparing a 1,2-ethanediamine in a ring opening reaction of an oxazolidinone, the process comprising contacting an oxazolidinone ...
  Transdermal thermal polymerization
The present invention, in one aspect, is a method for polymerizing or crosslinking by transdermal thermal energy a perpolymer which has been placed in the body of an ...
  Method for identifying an oligonucleotide aptamer specific for a target
We claim: 1. A method for identifying an aptamer which specifically binds to thrombin, wherein the aptamer comprises the sequence 5' GGNTGG 3' wherein N is A, T Or G ...
  Plant transcription regulators from circovirus
OF THE INVENTION The present invention is further described by reference to the following non-limiting figures and/or examples. Reference herein to a promoter region ...
  Methods for modulation of the effects of aging on the primate brain
The invention provides a clinically useful protocol for delivery of recombinant nervous system growth factors into the aging mammalian brain. The invention is ...
  Genetic engineering of cells to enhance healing and tissue regeneration
OF THE INVENTION It has been discovered that cells can be genetically engineered to produce bioactive molecules which act on the cells that are expressing the molecules,...
  Vascular endothelial growth factor-D (VEGF-D) polypeptides
OF THE INVENTION The invention will now be described in detail by reference to the figures, and to the following non-limiting examples. EXAMPLE 1 It has been speculated ...
  Methods for treating viral infection using IL-28 and IL-29
We claim: 1. A method of treating a viral infection comprising administering to an immunocompromised mammal with a hepatitis infection a therapeutically effective amount ...
  Method of manufacturing an electrohydraulic probe
OF THE INVENTION Referring to FIG. 1 there is shown a diagrammatical view of the bladder 2, ureter 4 and kidney 6 areas of a patient having a lithotriptoscope 8 moving ...
  Releasable linkage and compositions containing same
Accordingly, it is an object of the invention to provide a compound where a ligand is covalently yet reversibly linked to a hydrophilic polymer. Upon cleavage of the ...

0.084

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved